GALT — GALECTIN THERAPEUTICS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1133416 ·
Last close
$2.79
Market Cap
$183.74M
52W High
$3.50
52W Low
$2.03
ADV30
333,986
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -4,077,000 | -5,046,000 | 15,759,000 | 14,111,000 | 145,996,000 |
| Dec 2025 | 0 | — | -3,365,000 | -5,500,000 | 19,532,000 | 17,720,000 | 145,727,000 |
| Sep 2025 | 0 | — | -4,198,000 | -8,184,000 | 12,865,000 | 11,525,000 | 138,168,000 |
| Jun 2025 | 0 | — | -4,625,000 | -7,521,000 | 15,602,000 | 13,771,000 | 132,769,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-23,875,000
Investing CF
—
Financing CF
$26,475,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.58
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-432,546,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-23,507,000
Pretax Income TTM
$-30,836,000
Interest Exp TTM
$7,329,000
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -20,085,000 | -30,836,000 | 19,532,000 | 145,727,000 | — | -23,875,000 |
| Dec 2024 | 0 | -42,433,000 | -47,047,000 | 17,495,000 | 120,565,000 | — | -41,767,000 |
| Dec 2023 | 0 | -38,072,000 | -41,066,000 | 28,200,000 | 88,441,000 | — | -32,965,000 |
| Dec 2022 | 0 | -38,352,000 | -38,776,000 | 21,285,000 | 53,479,000 | — | -31,056,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.68
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $180.05M | $4.80 | — |
| UNCY | Unicycive Therapeutics, Inc. | $188.50M | $7.06 | — |
| RNAC | Cartesian Therapeutics, Inc. | $189.51M | $6.45 | — |
| KRRO | Korro Bio, Inc. | $177.83M | $12.33 | — |
| IMUX | IMMUNIC, INC. | $176.67M | $12.97 | — |
News headlines (Yahoo Finance, 1h cache)
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
2026-05-15 12:00 · Yahoo
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
2026-05-11 12:00 · Yahoo
Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?
2026-04-03 16:00 · Yahoo
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
2026-03-31 12:00 · Yahoo
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
2026-03-17 12:00 · Yahoo
Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps
2026-03-17 02:34 · Yahoo
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on
2026-02-26 21:05 · Yahoo
Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are retail investors with 55% stake, while 20% is held by insiders
2026-01-22 14:18 · Yahoo
Galectin Therapeutics Receives FDA Written Response on Belapectin, Adds $10 Million Credit Line
2025-12-19 14:50 · Yahoo
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures
2025-12-19 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.